Is there a sweet spot for Nrf2 activation in the treatment of diabetic kidney disease? (Q34077369)

30 July 2017

Is there a sweet spot for Nrf2 activation in the treatment of diabetic kidney disease? (English)

1 reference

30 July 2017

Evan T Hall

1

1 reference

PubMed ID

25146471

30 July 2017

Vivek Bhalla

series ordinal

2

1 reference

PubMed ID

25146471

30 July 2017

language of work or name

English

0 references

publication date

1 September 2014

1 reference

30 July 2017

2

1 reference

based on heuristic

inferred from page(s)

published in

Diabetes

1 reference

30 July 2017

63

1 reference

30 July 2017

9

1 reference

30 July 2017

2904-2905

1 reference

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

30 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4141365

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4141365

Bardoxolone methyl decreases megalin and activates nrf2 in the kidney

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4141365

Bardoxolone methyl and kidney function in CKD with type 2 diabetes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4141365

Temporal trends in the prevalence of diabetic kidney disease in the United States

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4141365

Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4141365

Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4141365

New therapies for diabetic kidney disease.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4141365

Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4141365

Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4141365

Derivative of Bardoxolone Methyl, dh404, in an Inverse Dose-Dependent Manner Lessens Diabetes-Associated Atherosclerosis and Improves Diabetic Kidney Disease

28 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25146471

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2337/DB14-0829

1 reference

30 July 2017

1 reference

30 July 2017

1 reference

PubMed ID

25146471